Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
ADNOC Gas Targets Up to $4B Profit in 2026 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
OpenAI Restricts Astra AI Over Cyberattack Risks 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Swiss pharmaceutical giant Novartis (SIX:NOVN) has reaffirmed its commitment to producing life-saving treatments for malaria and leprosy, even amid uncertainty over global health funding. According to Dr. Lutz Hegemann, President of Global Health at Novartis, the company will continue manufacturing its 28 million annual malaria treatment courses regardless of demand or funding disruptions.
Most of Novartis' antimalarial drugs are sold at a not-for-profit price to global initiatives, including the U.S.-funded President’s Malaria Initiative (PMI). However, recent aid cuts under President Donald Trump have threatened such programs. Earlier this year, a contractor for PMI canceled an order due to a government stop-work directive, but resumed the request shortly after receiving an exemption. “We are not going to be the bottleneck,” said Hegemann, emphasizing the company's commitment to maintaining supply even during funding gaps.
The Global Fund to Fight AIDS, Tuberculosis and Malaria remains the largest purchaser of Novartis' malaria treatments. While it has not yet faced funding cuts, it is actively seeking donations in a difficult financial environment.
Speaking from London, Hegemann urged the pharmaceutical industry to take a more proactive role in global health, advocating for deeper collaborations with low- and middle-income countries. He stressed that companies should go beyond merely compensating for shrinking donor aid and instead foster long-term public-private partnerships.
Novartis is also ramping up its R&D spending on malaria and neglected tropical diseases. The company expects to invest $490 million by 2025—nearly double its original $250 million pledge. Ongoing projects include a dengue antiviral, new therapies for leishmaniasis and Chagas disease, and the first malaria drug designed for newborns.
This strong commitment highlights Novartis’ leadership in global health and its resolve to support vulnerable communities worldwide.
